Are you over 18 and want to see adult content?
More Annotations
A complete backup of momsconfession.com
Are you over 18 and want to see adult content?
A complete backup of rospotrebnadzor.ru
Are you over 18 and want to see adult content?
A complete backup of jessicamccaw.com
Are you over 18 and want to see adult content?
A complete backup of parkeschampionpost.com.au
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of womendontask.com
Are you over 18 and want to see adult content?
A complete backup of konsumenteuropa.se
Are you over 18 and want to see adult content?
Text
getting started.
THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. CATEGORY: UNCATEGORIZED By Austin Walters, Managing Partner of SpringTide . Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground. ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTS sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. CATEGORY: UNCATEGORIZED By Austin Walters, Managing Partner of SpringTide . Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground. ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTS sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. CATEGORY: UNCATEGORIZED By Austin Walters, Managing Partner of SpringTide . Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground. ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTS sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. CATEGORY: UNCATEGORIZED By Austin Walters, Managing Partner of SpringTide . Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground. ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTS sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. CATEGORY: UNCATEGORIZED By Austin Walters, Managing Partner of SpringTide . Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground. ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTS sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. CATEGORY: UNCATEGORIZED By Austin Walters, Managing Partner of SpringTide . Living in a markedly different cultural environment, I began to learn that societies develop comparative strengths and weaknesses over time in response to conditions on the ground. ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTSDEFINE SPRINGTIDESPRINGTIDE NAILSSPRINGTIDE TRUMBULL sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. CATEGORY: UNCATEGORIZED The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.” ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTSDEFINE SPRINGTIDESPRINGTIDE NAILSSPRINGTIDE TRUMBULL sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. CATEGORY: UNCATEGORIZED The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.” ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
SPRINGTIDE INVESTMENTS SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year. PORTFOLIO - SPRINGTIDE INVESTMENTS sell into the market. . We formed SpringTide Ventures Fund I LP in 2018 as a platform to discover the best possible applications for cutting edge AI technology in medicine. We have invested broadly across specialties, care models, and customer types, each of our investments representing a distillation of our learning. We’re justgetting started.
WHAT WE’RE GOOD AT: SALES, SALES, SALES. PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with Elastic Sales, and subsequently leading PathologyWatch’s $5M THINKING - SPRINGTIDE INVESTMENTS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s $5M Series A round in WE ARE PURPOSE-DRIVEN SERIAL-ENTREPRENEURS DEMOCRATIZING We are a fund that is built by experienced founders, operators, and investors in the healthcare space. With over $350M in collective exits across 4 startup companies, our Managing Partners are driven to provide access and support for fellow entrepreneurs who are expanding access to quality medicine. PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS PathologyWatch Radically Improves Skin Cancer Diagnostics for Dermatologists. March 25, 2020. SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019 with Elastic Sales, building the in-house sales force, and led PathologyWatch’s$5M
SPRINGTIDE’S “N OF 1” PHILOSOPHY SpringTide’s “n of 1” Philosophy. The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.”. NECESSITY IS THE MOTHER OF INVENTION A remarkable book by Vijay Govindarajan called “ Reverse Innovation ” argues that innovations developed for consumers at the bottom of the global economic pyramid, i.e. the roughly 2 billion people living on less than $2 per day, share similar qualities of affordability and accessibility with the post-WWII Japanese disruptive innovations. CATEGORY: UNCATEGORIZED The idea is counterintuitive; everyone knows that in order to produce illuminating, actionable results, researchers should assemble large, diverse pools of research subjects – the largest they can handle – and see what insights they can skim out of this “Big Data.” ALGORITHMS DO NOT A COMPANY MAKE Algorithms Do Not A Company Make. The Health IT industry is full of companies touting useful inventions for patient care, workflow optimization and EMR upgrades. But ultimately, as every industry insider knows, there is a very high failure rate for new entrants. The high failure and premature exit rates among healthcare innovationcompanies can
Skip to content
* About
* Portfolio
* Sales
* Thinking
HELPING INNOVATIVE HEALTHCARE AI COMPANIES INCREASE SALES AND MAKE ADIFFERENCE.
SpringTide invests in AI companies that are solving big problems in medicine. As serial entrepreneurs, we look for teams that have strong technical leadership, multiple full-time founders, and strong immediate growth potential.Learn more
Thought Leadership
ALGORITHMS DO NOT A COMPANY MAKEMay 22
Read more
NECESSITY IS THE MOTHER OF INVENTIONApr 1
Read more
SPRINGTIDE’S “N OF 1” PHILOSOPHYApr 1
Read more
What differentiates SpringTide? PURPOSE-DRIVEN AND IMPACT SEEKING. We partner with leaders who are doing well by doing good. As serial health-tech entrepreneurs, we enjoy working with like-minded, mission-driven entrepreneurs on a mission to improve health and humanwellness.
Read more
ENTREPRENEURS SUPPORTING ENTREPRENEURS. SpringTide is a network of entrepreneurs who’ve pooled capital, access to great companies, and expertise to solve big problems inmedicine. Join us!
Read more
SCALING YOUR SALES TEAM WITH _ELASTIC SALES_. Say no to dead-end outsourced distribution deals and expensive premature sales forces. We have invented a better way to build a strong, value-accretive sales engine: Our proprietary _Elastic Sales_service.
Read more
Featured Case Study: PATHOLOGYWATCH RADICALLY IMPROVES SKIN CANCER DIAGNOSTICS FORDERMATOLOGISTS.
SpringTide was a Major Investor in PathologyWatch’s $3M Series Seed round in early 2019, taking a board seat. We continued to support the company through 2019, building the in-house sales force with _Elastic Sales_, and subsequently leading PathologyWatch’s $5M Series A round in early 2020, doubling the valuation within one year.Read more
SIGN UP FOR OUR NEWSLETTER Please enter your name. Please enter a valid email address.Submit
Something went wrong. Please check your entries and try again. SPRINGTIDE IS THE ONLY VENTURE HEALTH FUND THAT HELPS HEALTHCARE AI COMPANIES SOLVING BIG PROBLEMS SELL INTO THE MARKET FOR ENTREPRENEURS AND VENTURE PARTNERS ALIKE.* Home
* Thought Leadership* About Us
* Our Leadership & Advisors* Investment Thesis
* Portfolio Companies* Elastic Sales
* Investor Portal
* Contact Us
2021 SpringTide Capital Management LLCDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0